Table 2.
Summary of some selected retrospective stereotactic body radiotherapy series.
| Study | Design | Case and lesions | Dose (Gy) /fractions | Follow-up | Local control | Overall survival | PFS | Toxicity |
|---|---|---|---|---|---|---|---|---|
| Chang D 2011 | Retrospective | 65 patients 102 lesions |
22-60/1-6 | 1.2 (0.3-5.2) years | 1-year: 67% 2-year: 55% |
1-year: 72% 2-year: 38% |
NA | Grade 2 GI: 17% Grade 3 liver disease: 3% |
| Cazic D 2020 | Retrospective | 16 patients | 60/8 | 12 Mo | 1- year: 62.5% | 1-year: 87.5% | Median: 11 Mo | No Grade 3 |
| Nicosia L 2020 | Retrospective | 61 patients 97 lesions |
NA | 24 Mo | NA | Median: 23 Mo 1-year: 68.6% 2-year: 42.7% |
Median: 7 Mo | NA |
| de la Pena C 2020 | Retrospective | 24 patients 32 lesions |
NA | 22 (1-65) Mo | 1-year: 82% 2-year: 76.2% |
Median: 35 Mo 1-year: 85.83% 2 -year: 68% |
NA | No grade 3 No radiation-induced liver disease |
| Coffman A 2021 | Retrospective | 46 patients 81 lesions |
36-60/3 | 15 (1-54) Mo | 1-year: 92.5% | NA | NA | Grade 1: 37% Grade 2: 6.5% |
| Py J.F. 2021 | Retrospective | 67 patients 99 lesions |
37.5-54/3-5 | 47 (28-59) Mo | 1-year: 86.6% 2-year: 72.4% |
Median: 53Mo 1-year: 95.5% 5-year: 43.5% |
2-year: 54% | Grade ≥ 3: 3% |
| Yu J 2021 | Retrospective | 44 patients 62 lesions |
36-60/3-5 | 31.8 (3.2-122.9) Mo | NA | 1-year: 91% | NA | 0 |
| Stera S 2021 | Retrospective | 135 patients 227 lesions |
NA | 12.5 (0.5-84.3) Mo | 1-year: 90% 5-year: 68.7% |
1-year: 67% 2-year: 37% |
NA | NA |
| Voglhuber T 2021 | Retrospective | 115 patients 150 lesions |
35/5 | 11.4 Mo | Median: 35.1 Mo 1-year: 82% 2-year: 77% |
Median: 20.4 Mo 1-year: 72% 2-year: 45% |
Median: 4.3 Mo 1-year: 20% 2-year: 10% |
Grade 3: 8.7% |
Abbreviations: GI, Gastrointestinal; Mo, months; NA, not available; PFS, progression-free survival.